Objective To analyze clinical characteristics of posttransplant lymphoproliferativedisorder （PTLD） after pediatric liver transplantation, and to summarize its clinical diagnosis and treatment experience. Methods We retrospectively analyzed the clinical characteristics, laboratory data, radiological data, pathological result, treatment, and prognosis of 18 pediatric PTLD patients after liver transplantation presenting toBeijing Friendship Hospital from January, 2017 to September, 2019. Results A total of 18 patients were included in this study. The median age at surgery was 15.9 months （range, 4.6 ~ 146.7）, and the median onset time of PTLD was 15.1 months （range, 4.2 ~ 30.1） postoperatively. 88.9% （16/18） of patients had superficial lymphadenopathy, 94.4% （17/18） had Epstein-Barr viremia, and 88.9% （16/18） was EBER positive. In 17 patients, positron emission computed tomography （PET）-CT revealed increased FDG metabolism in the associated enlarged lymph nodes. All 18 patients underwent immunosuppression reduction, and were treated with targeted therapy, chemotherapy, surgery and adoptiveimmunotherapy with EBV-CTLs （EBV-specific cytotoxic T-cells） according to the pathological type. One patient died and 17 had clinical remission. ConclusionThe increased incidence of PTLD after pediatric liver transplantation may be related to EBV infection and high level of immunosuppression. The possibility of PTLD should be consideredin patients with EB-Viremia and superficial lymphadenopathy but without nonspecific symptoms. Monitoring EBVDNA replication load and reducing the level of immunosuppression are important means to treat PTLD in children after liver transplantation. Early diagnosis and treatment are of great significance to the prognosis of PTLD. 

Objective To analyze the short-term clinical effort of deceased donor（DD）kidneytransplantation from donors with cardiopulmonary resuscitation（CPR）. Methods A retrospective analysis was performed in 8 deceased donors who underwent cardiopulmonary resuscitation from January 2018 to May 2019. Six donors implemented organ donation according to cardiac death standard due to irreversible cardiac death （Maastricht Ⅳ）， while two donors implemented organ donation according to the brain death standard after successful cardiopulmonary resuscitation. A total of 16 patients received kidney transplantation from these eight donors. Shortterm renal allograft function and recipient/graft survival rate were evaluated. DGF， IGF，SGF， acute rejectionand pulmonary infection were followed up. Results During the follow-up period from 2months to18 months，the incidence of delayed graft function recovery （DGF）， immediate graft function recovery （IGF） and slow graft function recovery （SGF） were 56.25% （9/16），25%（4/16）， and 75%（12/16）. Two recipients showed primary graft non-function. The survival rate of recipients was 93.75% （15/16）， and the survival rate of death-censored recipients was 86.7%（13/15）. During the follow-up period， there was 1 case died of pulmonary infection and 2 cases experienced acute rejection. The lowest serum creatinine was （127±34）μmol/L in 14 patients with renal function recovery. Conclusion The incidence of DGF and SGF is high in patients who received kidneytransplantation from CPR donors， meanwhile the function of transplanted kidney recovers very slowly. The short-term survival effect is acceptable; However， the long-term effect needs further follow-up observation. 

Objective To investigate the effects of calcium dobesilate in the recovery of earlygraft function after renal transplantation. Methods A total number of 60 patients who received renal transplantation in our department during January 1st, 2018 to January 1st, 2019 were enrolled. The patients were randomly divided into treatment group who were treated with 500 mg calcium dobesilate, QD for 1 month and control group who were not treated with calcium dobesilate in the same period. Urine volume after transplantation, level of serum creatinine （Scr）, endogenous creatinine clearance （Ccr）, blood flow resistanceindexes （RI） of renal graft artery under Doppler Ultrasonic and the time required for serum creatinine to decrease under 120 μmol/L were compared. Results The urine volume after transplantation and CCr in treatmentgroup were significantly higher than those in control group, SCr, blood flow RI and the time required for serum creatinine to decrease under 120 μmol/L in treatment group were significantly less than those in control group. Conclusion Administration of calcium dobesilate in renal recipient is safe and effective for the recovery of early graft function after renal transplantation.